Literature DB >> 1923526

Frequent p53 mutations in chemically induced murine fibrosarcoma.

O Halevy1, J Rodel, A Peled, M Oren.   

Abstract

Patterns of p53 expression were investigated in chemically induced fibrosarcoma tumors and cell lines. Most, if not all, cell lines were found to carry alterations at the protein level, reflected in the overproduction of greatly stabilized p53 proteins. In many cases, this was accompanied by formation of complexes with hsc70. Hence, all of these lines may be expressing one sort or another of mutant p53. The mutant nature of the p53 gene was directly verified, in a number of cases, by PCR-amplified cDNA cloning. In one line, no p53 protein was made at all; this turned out to be because of a mutation in a splice donor site, resulting in the production of an aberrant mRNA. In all other cases, mRNAs carrying mis-sense mutations were present, and were sometimes expressed along with wt p53 mRNA. When tested in an in vitro transformation assay, all cloned mutants possessed a discrete oncogenic activity, while having lost the ability to interfere with oncogene-mediated transformation. The system described here could potentially be very helpful in elucidating the significance of p53 mutations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1923526

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

2.  Rat p53 gene mutations in primary Zymbal gland tumors induced by 2-amino-3-methylimidazo[4,5-f]quinoline, a food mutagen.

Authors:  H Makino; Y Ishizaka; A Tsujimoto; T Nakamura; M Onda; T Sugimura; M Nagao
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

3.  The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor.

Authors:  A Elkeles; T Juven-Gershon; D Israeli; S Wilder; A Zalcenstein; M Oren
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

Review 4.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 5.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

6.  p53 gene mutations and protein accumulation in human ovarian cancer.

Authors:  J Kupryjańczyk; A D Thor; R Beauchamp; V Merritt; S M Edgerton; D A Bell; D W Yandell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

7.  Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest.

Authors:  Y Barak; M Oren
Journal:  EMBO J       Date:  1992-06       Impact factor: 11.598

Review 8.  Current developments of targeting the p53 signaling pathway for cancer treatment.

Authors:  Jing Huang
Journal:  Pharmacol Ther       Date:  2020-10-29       Impact factor: 12.310

9.  Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes.

Authors:  A Zauberman; Y Barak; N Ragimov; N Levy; M Oren
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

10.  Titanium dioxide (TiO2) nanoparticles preferentially induce cell death in transformed cells in a Bak/Bax-independent fashion.

Authors:  Yanglong Zhu; John W Eaton; Chi Li
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.